Skip to content

US · EIKN · BIOTECHNOLOGY

Eikon Therapeutics, Inc. Common Stock (EIKN) intrinsic value and stock valuation

$4.74as of 2026-11-21 · Mkt cap 517.02M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Eikon Therapeutics, Inc. Common Stock DCF and intrinsic value

InvestorsCraft values EIKN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from EIKN’s statements →

Eikon Therapeutics, Inc. Common Stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Millbrae, CA 94030 eikontx.com

How the business is doing

Fiscal 2025–2025, USD

Revenue
$0.00
20252025
Net income
-$-324.25M
20252025
Free cash flow
-$-235.26M
20252025
Total equity
-$-879.03M
20252025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2025–2025, USD
2025
Revenue$0.00
Operating income-$-338.94M
Net income-$-324.25M
EPSd-$-5.99M
Operating cash flow-$-188.52M
Capital expenditure-$-46.74M
Free cash flow-$-235.26M
Total assets$594.7M
Total debt$257.3M
Net debt$152.4M
Total equity-$-879.03M
Cash and short-term investments$336M
Income statement
2025
Revenue$0.00
Cost of revenue$24.2M
Gross profit-$-24.18M
Research and development expenses$250.3M
Selling, general and administrative expenses$88.6M
Other expenses-$-24.18M
Operating expenses$314.8M
Cost and expenses$338.9M
Interest income$15.6M
Interest expense$840K
Depreciation and amortization$24.2M
Ebitda-$-299.24M
Operating income-$-338.94M
Total other income/expenses, net$14.7M
Income before tax-$-324.25M
Income tax expense$0.00
Net income-$-324.25M
Weighted average shares outstanding$54.1M
Weighted average diluted shares outstanding$54.1M
Balance sheet
2025
Cash and short-term investments$336M
Net receivables$0.00
Inventory$0.00
Total current assets$348.9M
Property, plant and equipment, net$233.9M
Goodwill and intangible assets$0.00
Long-term investments$0.00
Total non-current assets$245.8M
Total assets$594.7M
Accounts payable$680K
Short-term debt$10M
Deferred revenue$0.00
Total current liabilities$55M
Long-term debt$247.3M
Deferred revenue, non-current$0.00
Total non-current liabilities$1.42B
Capital lease obligations$257.3M
Total liabilities$1.47B
Common stock$0.00
Retained earnings-$-920.51M
Accumulated other comprehensive income (loss)$0.00
Total equity-$-879.03M
Total investments$231.1M
Total debt$257.3M
Net debt$152.4M
Cash flow statement
2025
Net income-$-324.25M
Depreciation and amortization$24.2M
Stock-based compensation$18M
Change in working capital$77.8M
Accounts receivable$0.00
Inventory$0.00
Accounts payable-$-3.81M
Net cash provided by operating activities-$-188.52M
Investments in property, plant and equipment-$-46.74M
Acquisitions, net$0.00
Net cash used for investing activities-$-181.34M
Common stock issued$1.9M
Common stock repurchased$0.00
Dividends paid$0.00
Net cash used for financing activities$352.1M
Net change in cash-$-17.81M
Cash at end of period$113.1M
Operating cash flow-$-188.52M
Capital expenditure-$-46.74M
Free cash flow-$-235.26M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Eikon Therapeutics, Inc. Common Stock

        Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.

        CEO
        Roger Perlmutter
        Employees
        384
        Beta
        0.86

        Explore

        Frequently asked questions

        What is the intrinsic value of Eikon Therapeutics, Inc. Common Stock (EIKN)?

        InvestorsCraft does not currently publish an intrinsic value for EIKN. How the IC value is calculated.

        Is EIKN undervalued?

        InvestorsCraft does not publish an undervaluation signal for EIKN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.